Publication Information

{'id': 'https://openalex.org/W4382025360', 'doi': 'https://doi.org/10.1093/bjd/ljad113.188', 'title': 'BI20 Generalized pustular psoriasis in a patient receiving pembrolizumab for metastatic lung adenocarcinoma', 'display_name': 'BI20 Generalized pustular psoriasis in a patient receiving pembrolizumab for metastatic lung adenocarcinoma', 'publication_year': 2023, 'publication_date': '2023-06-01', 'ids': {'openalex': 'https://openalex.org/W4382025360', 'doi': 'https://doi.org/10.1093/bjd/ljad113.188'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/bjd/ljad113.188', 'pdf_url': 'https://academic.oup.com/bjd/article-pdf/188/Supplement_4/ljad113.188/50698984/ljad113.188.pdf', 'source': {'id': 'https://openalex.org/S45720283', 'display_name': 'British Journal of Dermatology', 'issn_l': '0007-0963', 'issn': ['0007-0963', '1365-2133'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': True, 'oa_status': 'bronze', 'oa_url': 'https://academic.oup.com/bjd/article-pdf/188/Supplement_4/ljad113.188/50698984/ljad113.188.pdf', 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5002221059', 'display_name': 'Jeva Cernova', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I225661044', 'display_name': 'Barts Health NHS Trust', 'ror': 'https://ror.org/00b31g692', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I225661044']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Jeva Cernova', 'raw_affiliation_strings': ['Barts Health NHS Trust , London , UK'], 'affiliations': [{'raw_affiliation_string': 'Barts Health NHS Trust , London , UK', 'institution_ids': ['https://openalex.org/I225661044']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5107939188', 'display_name': 'Majeeda Patel', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I225661044', 'display_name': 'Barts Health NHS Trust', 'ror': 'https://ror.org/00b31g692', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I225661044']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Majeeda Patel', 'raw_affiliation_strings': ['Barts Health NHS Trust , London , UK'], 'affiliations': [{'raw_affiliation_string': 'Barts Health NHS Trust , London , UK', 'institution_ids': ['https://openalex.org/I225661044']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5092263528', 'display_name': 'Jinesh Dattani', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I225661044', 'display_name': 'Barts Health NHS Trust', 'ror': 'https://ror.org/00b31g692', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I225661044']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Jinesh Dattani', 'raw_affiliation_strings': ['Barts Health NHS Trust , London , UK'], 'affiliations': [{'raw_affiliation_string': 'Barts Health NHS Trust , London , UK', 'institution_ids': ['https://openalex.org/I225661044']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5024628157', 'display_name': 'Rebeca Goiriz', 'orcid': 'https://orcid.org/0009-0006-3548-5126'}, 'institutions': [{'id': 'https://openalex.org/I225661044', 'display_name': 'Barts Health NHS Trust', 'ror': 'https://ror.org/00b31g692', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I225661044']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Rebeca Goiriz', 'raw_affiliation_strings': ['Barts Health NHS Trust , London , UK'], 'affiliations': [{'raw_affiliation_string': 'Barts Health NHS Trust , London , UK', 'institution_ids': ['https://openalex.org/I225661044']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5110998234', 'display_name': 'Sukaina Rashid', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I225661044', 'display_name': 'Barts Health NHS Trust', 'ror': 'https://ror.org/00b31g692', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I225661044']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Sukaina Rashid', 'raw_affiliation_strings': ['Barts Health NHS Trust , London , UK'], 'affiliations': [{'raw_affiliation_string': 'Barts Health NHS Trust , London , UK', 'institution_ids': ['https://openalex.org/I225661044']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5044662843', 'display_name': 'Catherine Α. Harwood', 'orcid': 'https://orcid.org/0000-0002-1375-0965'}, 'institutions': [{'id': 'https://openalex.org/I225661044', 'display_name': 'Barts Health NHS Trust', 'ror': 'https://ror.org/00b31g692', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I225661044']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Catherine Harwood', 'raw_affiliation_strings': ['Barts Health NHS Trust , London , UK'], 'affiliations': [{'raw_affiliation_string': 'Barts Health NHS Trust , London , UK', 'institution_ids': ['https://openalex.org/I225661044']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': {'value': 3416, 'currency': 'GBP', 'value_usd': 4190, 'provenance': 'doaj'}, 'apc_paid': None, 'fwci': 0.319, 'has_fulltext': True, 'fulltext_origin': 'pdf', 'cited_by_count': 1, 'citation_normalized_percentile': {'value': 0.569213, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 67, 'max': 78}, 'biblio': {'volume': '188', 'issue': 'Supplement_4', 'first_page': None, 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10469', 'display_name': 'Psoriasis: Treatment and Pathogenesis', 'score': 0.9937, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10469', 'display_name': 'Psoriasis: Treatment and Pathogenesis', 'score': 0.9937, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9935, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11730', 'display_name': 'Autoimmune Bullous Skin Diseases', 'score': 0.9862, 'subfield': {'id': 'https://openalex.org/subfields/2734', 'display_name': 'Pathology and Forensic Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.91675925}, {'id': 'https://openalex.org/C2780564577', 'wikidata': 'https://www.wikidata.org/wiki/Q179945', 'display_name': 'Psoriasis', 'level': 2, 'score': 0.79851943}, {'id': 'https://openalex.org/C16005928', 'wikidata': 'https://www.wikidata.org/wiki/Q171171', 'display_name': 'Dermatology', 'level': 1, 'score': 0.73915994}, {'id': 'https://openalex.org/C2778570526', 'wikidata': 'https://www.wikidata.org/wiki/Q653197', 'display_name': 'Rash', 'level': 2, 'score': 0.66104066}, {'id': 'https://openalex.org/C2780057760', 'wikidata': 'https://www.wikidata.org/wiki/Q13896859', 'display_name': 'Pembrolizumab', 'level': 4, 'score': 0.6438327}, {'id': 'https://openalex.org/C2777014857', 'wikidata': 'https://www.wikidata.org/wiki/Q1383410', 'display_name': 'Exacerbation', 'level': 2, 'score': 0.51718533}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.5133607}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.3433785}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.25500798}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.09658086}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/bjd/ljad113.188', 'pdf_url': 'https://academic.oup.com/bjd/article-pdf/188/Supplement_4/ljad113.188/50698984/ljad113.188.pdf', 'source': {'id': 'https://openalex.org/S45720283', 'display_name': 'British Journal of Dermatology', 'issn_l': '0007-0963', 'issn': ['0007-0963', '1365-2133'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/bjd/ljad113.188', 'pdf_url': 'https://academic.oup.com/bjd/article-pdf/188/Supplement_4/ljad113.188/50698984/ljad113.188.pdf', 'source': {'id': 'https://openalex.org/S45720283', 'display_name': 'British Journal of Dermatology', 'issn_l': '0007-0963', 'issn': ['0007-0963', '1365-2133'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.87}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4281564228', 'https://openalex.org/W4200023723', 'https://openalex.org/W3041652591', 'https://openalex.org/W3037068108', 'https://openalex.org/W2945780494', 'https://openalex.org/W2891524425', 'https://openalex.org/W2585407512', 'https://openalex.org/W2521234799', 'https://openalex.org/W2517747645', 'https://openalex.org/W2062691140'], 'abstract_inverted_index': {'Abstract': [0], 'Skin': [1], 'toxicities': [2], 'are': [3, 69, 411], 'the': [4, 232, 303, 369, 403], 'most': [5], 'common': [6, 381], 'immune-related': [7], 'adverse': [8], 'events': [9], '(irAEs)': [10], 'associated': [11], 'with': [12, 91, 116, 242, 280, 383, 393, 399, 402, 409], 'immune': [13], 'checkpoint': [14], 'inhibitor': [15], '(ICI)': [16], 'treatment,': [17, 259], 'an': [18, 48, 379], 'emerging': [19], 'field': [20], 'in': [21, 82, 238], 'dermatology.': [22], 'A': [23, 113, 299], 'wide': [24], 'spectrum': [25], 'of': [26, 50, 70, 107, 136, 166, 174, 198, 226, 244, 268, 286, 295, 317, 323, 328, 372, 386], 'skin': [27, 38, 62, 221, 297], 'irAEs,': [28], 'including': [29], 'lichenoid': [30], 'reactions,': [31], 'vitiligo,': [32], 'bullous': [33], 'pemphigoid': [34], 'and': [35, 56, 73, 140, 176, 187, 223, 235, 251, 282, 289, 347, 356, 360, 390, 406], 'other': [36, 61], 'autoimmune': [37], 'diseases,': [39], 'have': [40, 184], 'been': [41, 80, 181], 'reported.': [42], 'Psoriasiform': [43], 'irAEs': [44, 291, 330], 'may': [45], 'occur': [46, 58], 'as': [47, 240, 333], 'exacerbation': [49, 243], 'pre-existing': [51, 93, 245], 'disease': [52, 363], 'or': [53, 401], 'de': [54], 'novo': [55], 'often': [57], 'later': [59, 263], 'than': [60, 84, 208, 337], 'irAEs.': [63], 'Most': [64], 'cases': [65], 'reported': [66, 81, 314], 'to': [67, 183, 249, 257, 272, 310], 'date': [68], 'chronic': [71], 'plaque': [72, 97, 186, 246], 'palmoplantar': [74], 'psoriasis.': [75, 276, 324], 'Generalized': [76], 'pustular': [77, 102, 275, 345], 'psoriasis': [78, 94, 103, 247, 288, 359, 377], 'has': [79], 'fewer': [83], '10': [85], 'cases.': [86], 'We': [87], 'present': [88], 'a': [89, 122, 134, 171, 218], 'patient': [90], 'mild': [92], 'who': [95], 'developed': [96, 121, 202], 'psoriasis,': [98, 175, 189], 'evolving': [99], 'into': [100], 'severe': [101], 'after': [104, 129, 164], '4': [105, 118], 'months': [106, 128, 197, 262], 'pembrolizumab': [108, 141, 250], 'therapy': [109], 'for': [110, 306, 368], 'lung': [111, 119, 167], 'cancer.': [112, 168], '67-year-old': [114], 'man': [115], 'stage': [117], 'adenocarcinoma': [120], 'widespread,': [123], 'itchy': [124], 'psoriasiform': [125, 290, 329], 'rash': [126, 233], '3': [127, 220], 'starting': [130, 199], 'pembrolizumab.': [131], 'He': [132, 169, 254, 277], 'had': [133, 146, 170, 179, 191, 320, 344], 'history': [135, 173, 322], 'rheumatoid': [137], 'arthritis': [138], '(RA)': [139], 'was': [142, 152, 157, 161, 236, 278], 'started': [143], 'when': [144, 159], 'he': [145, 178, 201, 270], 'progressed': [147, 271], 'through': [148], 'chemotherapy.': [149], 'The': [150, 214, 284], 'RA': [151], 'controlled': [153], 'on': [154], 'prednisolone,': [155], 'which': [156], 'increased': [158, 224], 'methotrexate': [160], 'discontinued': [162], 'shortly': [163], 'diagnosis': [165, 389], 'family': [172], 'although': [177], 'previously': [180], 'noted': [182], 'limited': [185], 'nail': [188], 'this': [190], 'required': [192], 'minimal': [193], 'treatment.': [194], 'Within': [195], '2': [196, 261], 'pembrolizumab,': [200, 269], 'scaly,': [203], 'red': [204], 'plaques': [205], 'affecting': [206], 'more': [207, 336], '30%': [209, 338], 'body': [210], 'surface': [211], 'area': [212], '(BSA).': [213], 'oncology': [215, 410], 'team': [216], 'diagnosed': [217, 237], 'grade': [219, 361], 'toxicity': [222], 'doses': [225], 'oral': [227], 'steroids.': [228, 253], 'Upon': [229], 'steroid': [230], 'tapering,': [231], 'flared': [234], 'dermatology': [239], 'consistent': [241], 'secondary': [248], 'high-dose': [252], 'partially': [255], 'responded': [256], 'skin-directed': [258], 'but': [260], 'following': [264], 'his': [265], 'sixth': [266], 'cycle': [267], 'generalized': [273], 'suberythrodermic': [274], 'treated': [279], 'acitretin': [281], 'methotrexate.': [283], 'incidence': [285], 'ICI-mediated': [287], 'is': [292, 378], 'approximately': [293], '4%': [294], 'all': [296], 'toxicities.': [298], 'cohort': [300], 'study': [301], 'by': [302], 'European': [304], 'Network': [305], 'Cutaneous': [307], 'Adverse': [308], 'Event': [309], 'Oncologic': [311], 'Drugs': [312], 'group': [313], 'that': [315, 395], '70%': [316], '115': [318], 'patients': [319], 'no': [321], 'Ten': [325], 'per': [326], 'cent': [327], 'were': [331, 364], 'categorized': [332], 'severe,': [334], 'involving': [335], 'BSA.': [339], 'However,': [340], 'only': [341], 'eight': [342], '(7%)': [343], 'involvement': [346], '2%': [348], 'erythroderma.': [349], 'Treatment': [350], 'options': [351], 'include': [352], 'acitretin,': [353], 'methotrexate,': [354], 'apremilast': [355], 'biologics.': [357], 'Guttate': [358], '2/3': [362], 'significant': [365], 'positive': [366], 'predictors': [367], 'antitumour': [370], 'response': [371], 'ICIs.': [373], 'In': [374], 'summary,': [375], 'ICI-related': [376], 'increasingly': [380], 'problem': [382], 'widespread': [384], 'use': [385], 'immunotherapy.': [387], 'Early': [388], 'adequate': [391], 'management': [392], 'agents': [394], 'do': [396], 'not': [397], 'interfere': [398], 'immunotherapy,': [400], 'underlying': [404], 'malignancy,': [405], 'close': [407], 'liaison': [408], 'crucial.': [412]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W4382025360', 'counts_by_year': [{'year': 2023, 'cited_by_count': 1}], 'updated_date': '2025-01-10T06:31:15.055239', 'created_date': '2023-06-27'}